The present invention generally pertains to methods of testing for the presence of anti-drug antibodies (ADAs) against therapeutic viral vectors. In particular, the present invention pertains to the use of biotin-labeled AAV as a capture reagent and ruthenium-labeled AAV as a detection reagent for the detection and quantification of ADAs against AAVs.

A reagent composition that is used as a first reagent composition for a method of quantifying small dense LDL cholesterol (sdLDL-C) in a sample, the method including causing the first reagent composition to act on the sample, and after the causing the first reagent composition to act on the sample, applying a second reagent composition for quantifying the sdLDL-C to quantify cholesterol in a remaining lipoprotein, in which the reagent composition has one or two or more activities selected from the group including cholesterol esterase activity, cholesterol oxidase activity, and sphingomyelinase activity, and contains polyoxyethylene monostyrenated phenyl ether.

A method for assaying endoglycosidase activity includes providing a proteoglycan having a glycosaminoglycan chain with a non-reducing end; treating the proteoglycan with a glycosyltransferase to incorporate a carbohydrate into the non-reducing end of the glycosaminoglycan chain, wherein the carbohydrate includes a click chemistry moiety; adding a label to the proteoglycan, wherein the label includes a click chemistry moiety that reacts to the click chemistry moiety of the carbohydrate such that the label attaches to the carbohydrate to form a labeled proteoglycan; immobilizing the labeled proteoglycan on a multi-well plate, wherein the multi-well plate includes a specific anti-proteoglycan antibody for binding the labeled proteoglycan; treating the labeled proteoglycan with an endoglycosidase specific to the glycosaminoglycan chain; and detecting the labeled proteoglycan.

Embodiments of the present disclosure relate to stabilized lactate oxidase compositions, and electrodes, sensors and systems that include the same. Also provided are methods for making the compositions and for detecting and/or measuring lactate in vivo with stable lactate enzyme compositions.

Disclosed is a magnetic nanostructure for detecting and isolating circulating tumor cells including a conductive polymer to which an antibody and magnetic nanoparticles are bound, which enables circulating tumor cells from early cancer patients and various circulating tumor cell types to be effectively detected using a small amount of blood, circulating tumor cells to be monitored with the naked eye through colorimetric detection, and a very small amount of circulating tumor cells present in blood to be efficiently captured with a strong magnetic field generated by a large amount of the loaded magnetic nanoparticles; in detecting, isolating, and collecting the circulating tumor cells in a very small amount, a long nanowire structure and various antibody types are used, whereby contact with cancer cells may be increased and strong bonding may be formed; sensitivity is increased and various interactions with cancer cells are facilitated, thereby exhibiting increased detection and isolation effects.

An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from redoxin proteins selected from the group consisting of thioredoxin; peroxiredoxin-1, 2 and 3; glutaredoxin-3; glutathione peroxidase-4; and nucleoredoxins for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen comprises detecting and/or measuring the amount of redoxin peptide fragments present in the biological sample of a subject.

A device for detecting and quantifying an analyte in a sample and a method of using the device includes a disposable cartridge having a microfluidic inlet for loading the sample having reporter probe-analyte-capture probe-magnetic bead complexes. A purifying chamber for purifying the magnetic bead complexes is also includes, as well as a measure chamber with a chip having electrodes. External electromagnets are situated each on opposite sides of the purifying chamber for retaining, or releasing or shaking magnetic bead complexes present in the purifying chamber. A permanent magnet is located under the working electrode of the measurement chamber to attract and retain the magnetic bead complexes on the surface of the working electrode of the chip. The device further includes a potentiostat for carrying out the electrochemical detection and quantification of the analyte.

Methods and systems are disclosed for analyzing and treating a fluid containing a peroxyacid and/or peroxide. A method of analyzing the fluid includes introducing into the fluid a decomposition agent that catalyzes decomposition of the peroxyacid and/or peroxide into decomposition products including oxygen, then directly or indirectly measuring an amount of oxygen produced after introduction of the decomposition agent, and determining an amount of the peroxyacid and/or peroxide present in the fluid. The amount of peroxyacid and/or peroxide in the fluid can also be monitored and controlled by further adjusting the amount of the peroxyacid and/or peroxide in the fluid based on the determined amount thereof. A system for performing the methods includes a decomposition agent infusion device for introducing the decomposition agent into a fluid sample, and a sensor for directly or indirectly measuring an amount of oxygen produced after introduction of the decomposition agent.

Methods of quantifying anti-HPA-1a antibodies in a sample, comprising (a) contacting the sample with a capture reagent that binds to the anti-HPA-1a antibodies to form a detection complex, wherein the capture reagent comprises a modified integrin psi and (b) measuring an amount of the detection complex, wherein the amount of the detection complex indicates the quantity of the anti-HPA-1a antibodies in the sample. The methods may also comprise contacting the sample with a detecting reagent that binds to the anti-HPA-1a antibodies and becomes part of the detection complex. The capture reagent and/or the detecting reagent may comprise a detection label, in which measuring the amount of the detection complex comprises measuring the amount of the detectable label.

This application provides methods and compositions related to real time monitoring targeted therapeutics by measuring time-dependent dynamics in distinct subpopulations of secreted vesicles. The technology utilizes bio-orthogonal probe amplification and spatial patterning of molecular reactions within plasmonic resonators to measure EV drug dynamics directly in patient blood samples. Small-molecule click probes are used in the assays for competitive, in situ target labeling in whole vesicles; the labeling of target by the probes can be enzymatically amplified to detect drug occupancy in EVs.